INCLINE VILLAGE, Nev., March 3 /PRNewswire-FirstCall/ -- PDL BioPharma, Inc. (PDL) today announced that John P. McLaughlin, the company's president and chief executive officer, will present at the Cowen and Company 30th Annual Health Care Conference in Boston on Tuesday, March 9, 2010 at 1:30 p.m. Eastern Time.
About PDL BioPharma
PDL pioneered the humanization of monoclonal antibodies and, by doing so, enabled the discovery of a new generation of targeted treatments for cancer and immunologic diseases. PDL is focused on maximizing the value of its antibody humanization patents and related assets. The Company receives royalties on sales of a number of humanized antibody products marketed today based on patents which expire in late 2014. For more information, please visit www.pdl.com.
CONTACT: Cris Larson of PDL BioPharma, Inc., +1-775-832-8505,
Cris.Larson@pdl.com; or Danielle Bertrand of WCG, +1-415-946-1056,
dbertrand@wcgworld.com, for PDL BioPharma, Inc.
Web site: http://www.pdl.com/
